Prior human endemic coronavirus exposure does not affect humoral responses to SARS-CoV-2 protein vaccines
We included measurement of pre-existing immunity to human endemic coronaviruses (HCoV) in a Phase I/II study of SARS-CoV-2 spike protein vaccine candidates. A Binding Antibody Multiplex Assay measured HCoV-specific IgG to the receptor binding domain or full-length spike of human coronaviruses HKU1, 229E, NL63, and OC43. We found no evidence for the impact of HCoV antibodies on neutralizing and binding antibody responses to the candidate SARS-CoV-2 vaccines.
Authors
- Sheetal Sawant (ORCID: https://orcid.org/0000-0002-1109-7907)
- Kelly E. Seaton (ORCID: https://orcid.org/0000-0002-2009-3270)
- Sarah V. Mudrak
- Caroline Brackett (ORCID: https://orcid.org/0000-0001-9371-6144)
- Georgia D. Tomaras (ORCID: https://orcid.org/0000-0001-8076-1931)
- Guy de Bruyn (ORCID: https://orcid.org/0000-0002-8028-4474)
- Lakshmanane Premkumar (ORCID: https://orcid.org/0000-0002-1736-1350)
- Saranya Sridhar (ORCID: https://orcid.org/0000-0002-4267-3102)
- Roman M. Chicz
- Haritha Adhikarla (ORCID: https://orcid.org/0000-0002-4217-2180)
- Donghui Zhang (ORCID: https://orcid.org/0000-0001-7258-8577)
Institutions
- University of North Carolina at Chapel Hill (US)
- Duke University (US)
- Sanofi (France) (FR)
- Sanofi (United States) (US)
- Orlando VA Medical Center (US)
- Sanofi (United Kingdom) (GB)
- Swift Engineering (United States) (US)
Publication Details
- Journal
- npj Vaccines
- Published
- 2025-07-13
- DOI
- https://doi.org/10.1038/s41541-025-01203-z
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Defense
- U.S. Department of Health and Human Services
- Bill and Melinda Gates Foundation
- GlaxoSmithKline
- Sanofi
- National Institutes of Health
- Biomedical Advanced Research and Development Authority
- National Institute of Allergy and Infectious Diseases